Science
Mechanism of Action
In murine models, D-Pulegone has demonstrated the ability to inhibit inflammatory pathways by suppressing the NLRP3 inflammasome and reducing specific cytokine production. It also exhibits general antioxidant and antibiotic effects. Crucially, at elevated concentrations, its metabolites can deactivate cytochrome P450 enzymes, leading to hepatic toxicity, characterized by vascular dilation and cellular necrosis.
Research
Clinical Evidence
Low confidenceN/A
Transparency
Dusting Analysis
The Cosmetic Ingredient Review (CIR) Expert Panel strictly limits D-Pulegone to 1% in cosmetic formulations due to substantial toxicity risks. This includes its classification as a Group 2B carcinogen (possibly carcinogenic to humans) and a chemical known to cause cancer under California's Prop 65. Exceeding this concentration presents unacceptable safety risks.
The Formula
Formulation
Stability
Reported to be stable under recommended storage conditions for the (R)-(+)-Pulegone enantiomer.
Safety
Safety Profile
The FDA does not authorize D-Pulegone as a synthetic flavoring substance. It is listed by the California Safe Cosmetics Program as a Group 2B carcinogen (possibly carcinogenic to humans) and a chemical known to cause cancer under Prop 65. The CIR Expert Panel mandates that its concentration in cosmetic formulations must not exceed 1% due to well-documented toxicity concerns.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Given its classification as a potential carcinogen under Prop 65, lack of FDA authorization, and strict 1% concentration limit due to toxicity, D-Pulegone poses significant safety concerns that far outweigh its documented anti-inflammatory and antioxidant benefits observed in non-human studies, making it unsuitable for precision skincare formulations.
Related
Similar Ingredients
Finding similar ingredients…